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Disease associated cardiologyStudies on naturally occurring New Zealand and Australian ovine models of the neuronal ceroid-lipofuscinoses
(Batten disease, NCLs) have greatly aided our understanding of these diseases. Close collaborations between
the NewZealand groups at LincolnUniversity and theUniversity of Otago, Dunedin, and a group at theUniversity
of Sydney, Australia, led to the formation of BARN, the Batten Animal Research Network. This review focusses on
presentations at the 14th International Conference on Neuronal Ceroid Lipofuscinoses (Batten Disease), recent
relevant background work, and previews of work in preparation for publication. Themes include CLN5 and
CLN6 neuronal cell culture studies, studies on tissues from affected and control animals and whole animal
in vivo studies. Topics include the effect of a CLN6 mutation on endoplasmic reticulum proteins, lysosomal func-
tion and the interactions of CLN6 with other lysosomal activities and trafﬁcking, scoping gene-based therapies, a
molecular dissection of neuroinﬂammation, identiﬁcation of differentially expressed genes in brain tissue, an
attempted therapy with an anti-inﬂammatory drug in vivo and work towards gene therapy in ovine models of
the NCLs. This article is part of a Special Issue entitled: "Current Research on the Neuronal Ceroid Lipofuscinoses
(Batten Disease)".
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Studies on naturally occurring ovine models of the neuronal ceroid-
lipofuscinoses (Batten disease, NCLs) have been central to our current
understanding of many aspects of this group of devastating childhood
neurodegenerative diseases. Currently mutations in 13 different genes
are described that lead to different forms [NCL mutation database;
http://www.ucl.ac.uk/ncl, [1]], but there may be more. Of these, muta-
tions in CLN6 lead to NCLs in New Zealand South Hampshire and
Australian Merino sheep [2,3], and in CLN5 to an NCL in New Zealand
Borderdale sheep [4,5]. Sheep have been domesticated for about
10,000 years, are bred for their amenability to humanhandling,mother-
ing properties and related factors that make them easy care, especiallyesearch on theNeuronal Ceroid
aculty of Agriculture and Life
New Zealand.
er).under Australian and New Zealand pasture management. Management
of sheep reproduction is well understood in our environments as are
the other husbandry skills for maintaining ﬂocks in good condition.
Veterinary care and animal science advice are easily accessible. These
three ovine models exhibit close clinical and pathological mimicry to
the relevant human NCLs. Anatomically, sheep have a human-like
gyrencephalic brain which, at 140 grammes by maturity, is larger than
that of many non-human primates, one-tenth that of a human adult
and more comparable to that of a neonate or small child.
Flocks of heterozygous ewes of each genotype have been established
and are mated with heterozygous or homozygous affected rams to pro-
duce affected (CLN−/−), heterozygous (CLN+/−) and homozygous nor-
mal (CLN+/+) lambs. These sheep have been subject to much research
over the last 40 years which has led to many advances in our under-
standing of Batten disease, reviewed in a number of publications
[6–10]. Highlights include determining the nature of the so-called
“lipofuscin-like” storage material, initially in what became the CLN6
form, later extended to the CLN5 ovine and bovine forms and many
human and murine forms; determining the regional nature of cortical
2280 D.N. Palmer et al. / Biochimica et Biophysica Acta 1852 (2015) 2279–2286atrophy and its close association with neuroinﬂammation, developing
neuron culture cell biology studies, and trialling therapeutic approaches.
Close collaborations have been a powerful driver, principally be-
tween Professor David Palmer's group at Lincoln University, New
Zealand, where the CLN5 Borderdale and CLN6 South Hampshire ﬂocks
are housed; the group led by Dr Stephanie Hughes at the University of
Otago, Dunedin, New Zealand who works mainly with neural cultures,
viral vector and gene therapy development and have a colony of nclf
CLN6 affected mice, and that led by Associate Professor Imke Tammen
in Sydney, Australia, where the CLN6 affected Merinos reside. Long-
term associations with Professors Jon Cooper at Kings College, London;
Sir John Walker, MRC Mitochondrial Biology Unit, Cambridge and Bob
Jolly and colleagues at Massey University, New Zealand are also invalu-
able. In order to make our collective intent clear we have formed BARN,
the Batten Animal Research Network, which has proved to be an invalu-
able brand for planning and resourcing coordinated studies and ﬁnanc-
ing them. Recent BARN initiatives were presented at a dedicated BARN
session at the 14th International Conference on Neuronal Ceroid
Lipofuscinoses (Batten Disease) and Patients Organization Meeting in
Córdoba, Argentina (October 22–26, 2014) and other BARN work was
presented in concurrent sessions at the meeting. This review focusses
on those presentations, including relevant backgroundwork completed
since the last reviews of sheepmodel studies [9–11], some unpublished
data and previews some of our current studies on ovine NCLs.
2. In vitro cell culture studies
Amethod for culturing embryonic ovine neural cells, based on those
used for rodent cell cultures, was established over a decade ago [12].
Primary neural cells have been recovered from ~60-day old (and occa-
sionally up to 120 day old) foetal brains by tryptic dissociation from ho-
mozygous CLN5 affected Borderdales, CLN6 affected South Hampshires,
heterozygous CLN+/− sheep of both genotypes and control sheep, and
stored frozen [13,14]. These ovine primary cell cultures, consisting of a
mixed population of neural precursors (neuroblasts), mature neurons,
astrocytes and microglia [13], have been extensively characterised and
are used as in vitro cell biology models to investigate key issues in
CLN5 and CLN6 disease pathology, as well as providing assay systems
to develop and test novel therapeutics.
2.1. Storage bodies in cultured neural cells
Once established from thawed cells, ovine CLN5 and CLN6 neural
cells can be maintained in culture routinely for three to four weeks,
although maintenance up to a few months has been achieved, by
judicious use of conditions to stop glial cell take-over of the cultures. A
high proportion of cells adhere as neurons [13]. These cultures have
been used to unravel a number of important changes in CLN6−/− cul-
tured neurons, including time-dependent accumulation of subunit c
containing ﬂuorescent storage bodies [15] and a loss of GABAergic neu-
rons [16]. They provide a convenient platform in which to investigate
prenatal synaptic pathologies in ovine CLN5 and CLN6 NCLs, the mech-
anisms by which these alterations occur, and in which novel drug com-
pounds and viral-mediated gene overexpression and correction
techniques can be investigated for effectiveness at correcting the
numerous identiﬁed synaptic and lysosomal pathologies before pro-
gression into in vivo trials.
Recent experiments showed that accumulation of storage material
in CLN5−/− cultures was reversed following lentiviral-mediated over-
expression of C-terminalmyc-tagged CLN5 [14]. Dissociatedmixed neu-
ral cells from CLN5−/− foetal sheep brains had no obvious storage
material at plating; however, storage material was obvious and wide-
spreadwithinmicroglia, neurons and astrocytes aweek later. Transduc-
tionwith the CLN5-containing lentiviral vector after thisweek in culture
rapidly reversed the storage accumulation, more than half the storagebodies being removed in an autophagic process in the 6 days following
transduction [14].
2.2. Effect of a CLN6 mutation on endoplasmic reticulum proteins
CLN6 is thought to be an endoplasmic reticulum (ER) resident pro-
tein [17,18] so its effect on other ER proteinswas analysed using immu-
nocytochemistry for a soluble ER marker protein (protein disulphide
isomerase, PDI) and a membrane-associated ER marker (calnexin).
Whilst PDI is present in both control and CLN6−/− cultures, calnexin is
signiﬁcantly reduced in affected cells (Fig. 1), perhaps indicating a de-
crease in expression, or misprocessing or folding in the absence of func-
tional CLN6. Further studies are required to resolve these possibilities.
2.3. Interactions of CLN6 with other lysosomal activities and trafﬁcking
The broadly similar pathological and clinical proﬁles of the different
NCLs suggest that commonmolecular pathways might link the NCL dis-
ease variants together, despite the differing primary genetic defects.
Several studies support the hypothesis that CLN-proteins interact and
are involved in a common pathway but solid evidence for molecular
links between the NCLs is still scant, and in some cases the evidence is
contradictory. A co-localisation/co-immunoprecipitation study report-
ed that CLN2, CLN3, CLN6, and CLN8 proteins co-localise and co-
immunoprecipitate, and that the addition of the CLN2 protein (TPP1)
to cell lines deﬁcient in CLN3, 6, or 8 corrected growth and apoptosis
[21]. Another pull-down and co-immunoprecipitation study found evi-
dence to suggest that CLN5 is a central interaction partner andmay play
an important role in connecting different NCL (CLN) proteins [22]. CLN5
was found to interact with CLN1, CLN2, CLN3, CLN6, and CLN8. These
data also suggest that CLN5 has the capacity to bind proteins from dif-
ferent subcellular compartments as both lysosomal and ER proteins
are suggested as CLN5 binding partners.
Although the function of CLN6 is yet to be elucidated, given the
above data and the ER localisation of CLN6 protein, it is sensible to
hypothesise a role for CLN6 in protein trafﬁcking pathways, particularly
in a network involving other NCL-associated proteins and enzymes. It
has been suggested that CLN6 plays a role in endocytosis of lysosomal
proteins. The endocytic pathway is reported to be reduced in neuronal
cells of vLINCL patients [17,18], as is the synthesis rate of mutant
CLN6. It is also hypothesised that CLN6 mediates selective transport of
lipids and proteins essential for the function and acidiﬁcation of the ly-
sosome [18]. This hypothesis arises from the reported increase in lyso-
somal pH in ﬁbroblasts from a CLN6 patient [23].
These hypotheses led to an investigation of the effect of the ovine
South Hampshire CLN6 mutation on NCL-associated soluble lysosomal
enzyme activities to determine whether this alters the activity of vari-
ous NCL-associated enzymes. Three NCL-associated lysosomal enzymes
were investigated; CLN1, CLN2, and CLN10, and a non-NCL associated
lysosomal enzyme, β-hexosaminidase, was also included. Palmitoyl
protein thioesterase 1 (PPT1, CLN1), tripeptidyl proteinase 1 (TPP1,
CLN2) and the lysosomal β-hexosaminidase enzymatic rates were com-
parable across CLN6−/− and control derived neural cell lysates (Fig. 2),
indicating that this CLN6 mutation does not disrupt the trafﬁcking of
these lysosomal enzymes to the lysosome. They are able to be processed
and trafﬁcked correctly in the absence of functional CLN6 protein. How-
ever, CLN6−/− primary cell lysates demonstrated a signiﬁcant, albeit
small, decrease in Cathepsin D enzymatic activity, as compared to con-
trol cell lysates (Fig. 2c).
These results indicate functional processing and trafﬁcking of these
three lysosomal enzymes within CLN6−/− cells during the neural cell
culture maintenance period. If these pathways were not functional the
enzyme activity would be greatly reduced, and the proteins must
reach the lysosome in their fully modiﬁed and folded mature form in
order to function as enzymes. This would not be so if the CLN6 protein
Fig. 1.Calnexin immunoreactivity is reduced in CLN6−/− cultures. Primary ovine neural cell cultures (embryonic day 68–70)were plated at 2 × 105 cells/cm2 as described [13,19] and ﬁxed
in 4% phosphate-buffered paraformaldehyde eight days later. a–b Calnexin was detected with an anti-calnexin antibody (GeneTex, USA #GTX109669; 1:200) and Alexa Fluor 488 goat
anti-rabbit IgG (Life Technologies, USA, A-11008, 1:1000). Cells were counterstained with DAPI for nuclei (blue), scale bar 20 μm; or c–d, protein disulphide isomerase (PDI) using anti-
bodies raised against human PDI [20], scale bar 100 μm. Single 0.2 μm confocal slices were acquired on a Zeiss 510 LSM confocal microscope (Zeiss, Germany). Note the decrease in anti-
calnexin immunoﬂuorescent intensity in CLN6−/− cultures compared to controls. Average ﬂuorescence intensities were measured using the Measure RGB macro in Image J (NIH, USA).
Five ﬁelds were analysed from three individual foetal preparations per genotype. The calnexin data in e) are signiﬁcantly different, p b 0.05, whereas there is no signiﬁcant difference be-
tween the PDI signals in f.
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of the newly synthesised proteins to their correct cellular destination.
2.4. In vitro testing of gene-based therapies
The neural cell cultures are also extremely useful for scoping the
possibilities for gene based therapies. Lentiviruses have proven to be
versatile gene delivery vectors in many lysosomal storage diseases
[24–26], and can transduce a wide range of cell types, integrating into
the host genome of both dividing and post-mitotic cells and resulting
in long-term stable expression of the transgene. To explore their useful-
ness in NCL gene therapy, lentiviral-mediated transduction efﬁciency,
transgenic expression, and cell tropism were tested in cultures from
both affected South Hampshire (CLN6) and Borderdale (CLN5) sheep.
Lentiviral vectors were pseudotyped with the vesticular stomatitis
virus glycoprotein, VSV-g, with transgene expression under the control
of a constitutive myeloproliferative sarcoma virus promoter to prefer-
entially target neurons, as tested in other model organisms [27].
Delivery of a green ﬂuorescent protein (GFP) reporter genewas demon-
strated in both control and CLN6 affected neural cultures, with a greater
tropism for neuronal and neuroblast cells than glia [19]. This, alongwith
the signiﬁcant diminution of storage body ﬂuorescence observed in
CLN5-deﬁcient neural cells after transduction with a CLN5 expressing
lentiviral vector noted above [14], supports the use of lentiviral mediat-
ed gene transfer in ovine NCL in vivo.
3. Comparative CNS and visceral histopathology,
immunohistopathology and tissue extract studies
Over the years we have been accumulating and replenishing stocks
for various tissues and extracts from the CLN5 and CLN6 affected
sheep and controls at different stages of disease development. These
allow longitudinal comparisons of various changes to be made. Ideally
tissues and extracts from three animals at each age (birth, 1, 2, 4, 6, 9,
12, 15, 18 months), as well as at an advanced disease (18 months and
older) are retained, but sometimes there are shortfalls, which we ﬁllin when possible. Collections include perfusion ﬁxed brain hemispheres
from CLN5 and CLN6 affected and age-matched control sheep at all
stages of disease progression, cryopreserved, awaiting cryosectioning
or cut (sagittally and coronally) and catalogued ready for immunostain-
ing. These include the cerebellum. Studies comparing the longitudinal
pathology of all three genotypes (Borderdale CLN5, and the CLN6muta-
tions in South Hampshire andMerinos) are underway. Results so far in-
dicate that the courses of these diseases are remarkably similar,
especially so given the diversity of the underlying genetic defects.
Also on hand is a collection of fresh frozen brain blocks for the isola-
tion of protein and total RNA/mRNA from selected brain regions at all
stages of disease. These are 6mm thick sagittal sections, cut immediate-
ly post mortem, snap frozen in liquid nitrogen and stored at−80 °C after
being catalogued. Speciﬁc brain regions are dissected from these slabs
for RNA or protein extraction. Complementary DNA (cDNA) is generat-
ed via reverse transcriptase (RT) reactions and then stored at−80 for
future quantitative PCR analyses.
Sheep are routinely diagnosed from blood samples taken at weaning
or at the time of euthanasia [2,5], which are then stored as dry spots
catalogued for DNA extraction. Fresh, frozen and ﬁxed samples of
various visceral tissues and organs, including eyes, complete these
collections.3.1. A molecular dissection of neuroinﬂammation
Following earlier histological investigations, glial activation
characterised by astrocytosis and microglial activation has long been
considered to be a generalised response in the NCLs [7,8,28]. This was
extended in comprehensive immunohistochemical studies using the
ovine CLN6 sagittal sections above to show that glial activation begins
perinatally, proceeds regionally, starting in regions associated with
early clinical symptoms, and precedes neurodegeneration [29–31].
The parieto-occipital cortex is affected ﬁrst, before neuroinﬂammation
and subsequent neurodegeneration becomes more generalised within
other cortical regions. The cerebellum remains largely unaffected,
Fig. 2. The enzymatic activities of PPT1 (CLN1), TPP1 (CLN2), Cathepsin D (CLN10) and β-hexosaminidase in control and CLN6−/− cultured neural cell lysates. Sheep neural cell cultures
from 3 control and 3 CLN6−/− foetuses were harvested into lysis buffer containing 0.1% Triton-X, 0.15M NaCl, and protease inhibitors, aprotinin, leupeptin, pepstatin and PMSF. a. PPT1/
CLN1 enzymatic rates were measured (Moscerdam Substrates, the Netherlands), in samples containing 28 mg/mL protein from the hydrolysis of 4-methylumbelliferyl-6-thiopalmitoyl-
beta-D-glucoside using a 4-MU standard curve. Enzymatic rates did not differ signiﬁcantly between control and CLN6−/− neural cell lysates, b. For TPP1/CLN2 activities, 100 mg/mL total
protein lysate was incubated in citrate buffer, pH 4.5, at 37 °C for 60 min. to allow activation of TPP1, then 5 μM Ala-Ala-Phe 7-amido-4-methylcoumarin (AAF-AMC) added, ﬂuorescent
readings taken every 2 min. for 40 min. at 37 °C with 380 nm excitation and 460 nm emission and TTP1 activities quantiﬁed by comparison to an AMC standard curve. There was no sig-
niﬁcant difference in activities between control and CLN6−/− neural cell lysates. c. Cathepsin D/CLN10 assayed ﬂuorometrically (Cathepsin D activity assay kit, Abcam, UK; ab65302), was
slightly lower in affected cells than in controls, p b 0.05. d. β-hexosaminidase activity determined following a two-hour incubation of 25 mg/mL neural cell lysate with 25 μg/mL 4-
methylumbelliferylN-acetyl-β-D-glucosaminide dehydrate (4-MUGS) did not differ signiﬁcantly between genotypes. In all data sets, the black bar values relate to individual foetal samples
of each genotype, and red bars show the genotype mean value (+/−SEM).
Fig. 3. A proposed neuroinﬂammatory pathway in ovine CLN6 Batten disease, based on the literature [39–46].
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amus or hypothalamus [32].
From these ﬁndings a hypothesis was developed, that since neuroin-
ﬂammation precedes neurodegeneration, it may be causative of it and
drug inhibition or suppression of the neuroinﬂammatory pathway
might provide a therapy. Whole animal experiments revealed that
targeting is required (see 5.2 below). Subsequently amolecular dissection
of the neuroinﬂammatory cascade was initiated, to determine the points
of lesion in the NCLs for effective and target-speciﬁc drug intervention
[33]. This was based on a proposed neuroinﬂammatory pathway (Fig. 3)
which includes components of pro- and anti-inﬂammations, oxidative
stress, neuronal survival via mediation of neurotrophic factors and
breaching of the blood–brain-barrier.
The expression of a number of neuroinﬂammatory modulators
(TNF-α, TGF-β, IL-1β, IL-10, NF-ƙB, MnSOD, iNOS, JAK2, STAT 1 and 3,
SOCS3, TrkB and BDNF) was investigated in different brain regions at
different ages of disease development [35]. Expressions of other genes
that have been proposed to be involved in the pathogenesis of NCLs,
such as metallothioneins and progranulin [36–38], were also selected
for investigation. Different inﬂammatory mediators were expressed
differently in affected animals. Both pro- (TNF-α and IL-1β) and
anti-inﬂammatory cytokines (TGF-β and IL-10) were up-regulated
and suppression of cytokine signalling mediated by SOCS3 was activat-
ed dramatically at the initiation of neurodegeneration. NF-ƙB and JAK2
activation followed whereas the oxidative responsive genes MnSOD
and iNOSwere not activated. TrkB expression increased at the advanced
disease whilst BDNF expression remained unchanged.
Only SOCS3wasunequivocally upregulated prior to neuroinﬂamma-
tion and many of the other changes in gene expression proﬁles are
unlikely to be causative. This study also highlights the weakness of
building scenarios based on observed changes in single gene expres-
sions in isolation. A similar study of CLN5 ovine Batten disease under-
way will indicate the generality of these ﬁndings. A change of strategy
is planned to continue these studies. Given the large number of changes
observed, a transcriptomic approach is probably more appropriate.
3.2. Transcriptomics
Apreliminary studyusingRNA-sequencing (RNA-seq) has been con-
ducted to determine if a whole transcriptomic approach has the ability
to identify the principal/primary molecular changes during early dis-
ease and its progression [47]. RNA-seq is a next generation sequencing
method that allows the quantiﬁcation of gene expression as well as
the identiﬁcation of alternative splicing isoforms and transcript start
sites [48–50]. In this pilot study, eight brain samples from CLN6 affected
Merino and control sheep were used to investigate differential gene ex-
pression between normal and affected frontal brain tissues at three and
fourteen months of age. Tissue samples collected at euthanasia were
stored in RNAlater solution (Life Technologies, USA) at−80 °C for 16
to 17 months. RNA was extracted with TRIzol (Life Technologies),
followed by on-columnDNase treatmentwith the RNeasyMidi Cleanup
Kit (Qiagen, Germany). RNA integrity was assessed using the 2100
Bioanalyzer (Agilent Technologies, Inc., USA). Library preparation,
using the TruSeq Stranded Total RNA with Ribo-Zero Gold (Illumina,
USA), and paired-end sequencing using an Illumina HiSeqTM platform
were performed at the Australian Genome Research Facility (http://
www.agrf.org.au). Sequencing reads were aligned to the sheep genome
using TopHat (http://tophat.cbcb.umd.edu/) [49] and analysed with
Cufﬂinks (http://cufﬂinks.cbcb.umd.edu). Cuffmerge and Cuffdiff
(http://cufﬂinks.cbcb.umd.edu/) [50] were used to identify differential-
ly expressed genes. Genes that showed signiﬁcant differential expres-
sion (q-value b 0.05) were analysed further using the Database for
Annotation, Visualization and Integrated Discovery (DAVID) 6.7
(http://david.abcc.ncifcrf.gov/) [51].
Nineteen genes showed signiﬁcant differential expression between
the frontal regions of two affected and two normal 3 month old sheep,18 being up-regulated and one down-regulated in the affected animals.
When the gene expressions in the frontal regions of two affected sheep
at 3 months were compared to two 14 month old affected sheep, 135
genes were up-regulated in the affected animals, and 65 down-
regulated. Preliminary gene ontology analysis associated differential
gene expression patterns with the induction of inﬂammation, cell
surface receptor linked signal transduction, cellular andmetal ion trans-
port, tissue remodelling (activation and inactivation of genes associated
with actin, myotubules, cell-adhesion) and apoptosis.
This study indicates that RNA-seq is a useful tool for studying disease
mechanisms in theNCLs, highlighting the diversemolecular changes ac-
companying neurodegeneration and the inﬂammatory mechanisms
that play an important role in disease progression. Howvariations in tis-
sue storage times inﬂuence RNA integrity is a concern in longitudinal
transcriptomic studies. Uncertainty was minimized in this study as all
samples were stored for similar lengths of time from sheep born over
two consecutive years. Future studies will use greater read depth
RNA-seq analyses in tissues from all our ovine NCL and cell culture
models, to develop a better understanding of the transcript proﬁle of
CLN5 and CLN6, increase our understanding of the pathogenic cascade,
and evaluate the molecular effects of gene therapy agents.
3.3. The role of metals in NCL pathogenesis
BARN also provides tissues and organs for others to pursue indepen-
dent lines of enquiry. Recently there has been a renewed interest in the
role of biometal disturbances, as they are now called, in the NCLs. Tis-
sues from both the Merino and South Hampshire sheep have been
analysed for the possible involvement of disruptions of biometals in
the pathogenesis of disease. Increased zinc and manganese concentra-
tions in parallel with neurodegeneration, synaptic protein changes
and activation of Akt/GSK3 signalling in ovine CLN6 neuronal ceroid
lipofuscinosis was reported [37]. Deregulation of subcellular biometal
homeostasis through loss of the metal transporter, Zip7, in CLN6 vari-
ants was also reported and a direct link between an apparent loss of
control of biometal homeostasis and pathogenesis claimed [52].
These claims of links between changes in metal concentrations and
pathogenesis should be treated with caution. An analysis of the concen-
trations of a wide range of metals in storage bodies from different tis-
sues in CLN6 affected sheep indicated no such links, and that the
metals arise from the storage bodies having a history of active regula-
tion of metal homeostasis as part of their histories as active lysosome
derived organelles [53].
4. Whole animal in vivo studies
The ﬂocks of animals at Lincoln and in Sydney provide 10–20 affect-
ed lambs of each breed each year, which are harvested at different times
for the in vitro and postmortem studies described above. They are also an
invaluable resource for whole animal in vivo studies. Sheep have excel-
lent facial recognition capability, long-term learning and spatial memo-
ry skills [54–56] and a relatively long lifespan that can extend to teenage
years. Their anatomy, physiology and genome are more similar to those
of humans than of mice. We have well deﬁned records on the clinical
course of the ovine diseases, and have established protocols for perfor-
mance testing in sheep for longitudinal in vivo assessment of therapeu-
tic efﬁcacy. These include behavioural, cognitive and neurological
parameters and quantitative computer tomography (CT) and magnetic
resonance imaging (MRI).
4.1. Behavioural, neurological and physiological studies
Biomarkers (sometimes called readouts) are extremely useful for
measuring the progress of disease-modifying therapies, be they func-
tional, behavioural or physiological. Practical in vivo biomarkers have
been established for all three sheep models for assessing therapeutic
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and homozygous normal sheep were compared at 3–5 week inter-
vals, between 26 and 60 weeks of age for progressive postural, be-
havioural and live-weight changes [57]. Signiﬁcant differences
were found between weight gains (affected sheep gained weight
more slowly) grazing behaviour (affected sheep spent less time
grazing), ambulatory behaviour (affected sheep spent more time
walking), steps taken per day (affected sheep took more steps),
and responsiveness to visual and auditory stimuli (affected sheep
showed a progressive reduction in responsiveness). A composite
variable of key behaviours was identiﬁed in a principal components
analysis (scores for affected sheep increased more rapidly than con-
trols). In the future, frequent monitoring of relevant indicators using
automatic recording technology, would facilitate the assessment of
disease progression in therapy trials.
Automatic recording technology has already been used to re-
cord electroencephalography (EEG) changes in CLN5 affected
Borderdale sheep in a longitudinal study spanning many months
[58]. Twenty-four hour recordings were collected via surgically im-
planted electrodes and vigilance states and neurophysiological
hallmarks, such as sleep spindles, quantiﬁed. Mild sleep abnormal-
ities, decreased amplitude and abnormal epileptiform waveforms
in the EEGs of affected sheep resemble those seen in children
with Batten disease, demonstrating the translational relevance of
the NCL sheep models.
Electrocardiography has also been explored in ovine NCL. Various
studies have reported cardiac abnormalities such as repolarization dis-
turbances, ventricular hypertrophy and sinus node dysfunction in pa-
tients with various forms of NCL [59–64]. Possible cardiac pathology
was investigated in the CLN6 affectedMerino sheep. Electrocardiograms
(ECGs) were conducted on affected and clinically normal control sheep
at approximately 13 and 20months of age, corresponding to mid-stage
and late-stage diseases. Analysis of the ECG and echocardiographic data
did not reveal any abnormalities in the affected sheep, nor was storage
material found in their heart valves, myocardium, or the sinoatrial or
atrioventricular nodes by histology. Most sections from all sheep
showed somedegree ofmyocardial sarcocystosis whichwas considered
an incidental ﬁnding. This study did not indicate any cardiac involve-
ment in CLN6 NCL in Merino sheep.4.2. Attempted therapy with an anti-inﬂammatory drug in vivo
The ﬁnding that neurodegeneration is consequent to neuroin-
ﬂammation and likely to be caused by it [29,31], led to a study to
determine if early chronic administration of minocycline, an anti-
inﬂammatory drug, would halt or reverse the development of
disease [65]. Minocycline is a tetracycline with broad anti-
inﬂammatory properties [66–68]. It was administered orally to
CLN6 affected South Hampshire lambs from three to 14 months of
age. The minocycline was absorbed without signiﬁcant rumen bio-
transformation to maintain pharmacological concentrations of
1 μM in plasma and 400 nM in cerebrospinal ﬂuid, but these did
not result in inhibition of microglial activation or astrocytosis and
did not change the neuronal loss or clinical course of the disease.
This indicates that minocycline does not inhibit a critical step in
the neuroinﬂammatory cascade in the CLN6 form, that the
neuroinﬂammatory cascade is complex and that targeted selection
of candidate drugs is required for this strategy to be effective. How-
ever the mode of anti-inﬂammatory action of minocycline is unclear.
Identiﬁcation of the critical steps in the neuroinﬂammatory cascade
will greatly increase the likelihood of success this strategy, stimulat-
ing a molecular dissection of the neuroinﬂammatory cascade in
these diseases (see Section 4.1). They also highlight the wisdom of
animal model studies preceding highly speculative procedures in
humans.4.3. Gene therapy in ovine models of the NCLs
Gene therapy is an exciting prospect for the treatment of lysosomal
storage diseases, including the NCLs. Approaches described in murine
models of NCLs [69,70] have been extended to clinical trials in humans
for the CLN2 form [71,72]. Because of their closer similarity to humans,
therapy development in sheep should offer better data than mice; on
vector titres, doses and target sites and should bemore predictive of ac-
tual clinical outcomes.4.3.1. Development of gene therapies
Following efﬁcient lentiviral mediated gene transfer to neurons in
culture [19], a programme of direct injections into sheep brains in vivo
was initiated. No transduction of cells followed intracisternal injections
of lentiviral GFP constructs in sheep, however columnar infusion into
the cortical parenchyma resulted in stable yet localised GFP transduc-
tion evident up to 80 day post-injection [19]. Of importance was the
targeted transduction of ependymal and subependymal cells along the
extent of the ventricular surface, including type B astrocytic cells,
thought to be the bona ﬁde adult neural stem cells. These ﬁndings
were encouraging for human translation. Correction of the ependyma
lining the ventricles could result in protein secretion into the cerebral
spinal ﬂuid (CSF) for circulation to the entire CNS whilst transduced
neuroblasts could provide an alternative route for spread of the gene
product to the degenerating cortex in NCL patients via the chain migra-
tion of neuroblastic granule cells.
In the next set of experiments, juvenile CLN5 and CLN6 affected
sheep received lentiviral vectors containing the respective CLN5
and CLN6 transgenes with attached myc tags, with concurrent deliv-
ery of GFP-containing vector, injected directly into the brain paren-
chyma and the ventricular system. Animals were pre-clinical when
injected but the doses were low (100- to 1000-fold less than in
subsequent trials). Successful delivery of CLN5 and CLN6 to the
affected sheep brain was demonstrated; however, no neurologic or
behavioural amelioration resulted; an outcome attributed to the
sub-therapeutic vector doses.
Adeno-associated viral (AAV) vectors, now often preferred for gene
therapy studies because of their marked long-term transduction efﬁ-
ciency and spread, have been recently trialled in sheep [73]. A broad
transgene distribution throughout the CNS was evident a month after
intraventricular delivery of AAV9-GFP to the normal sheep brain, clus-
ters of GFP-positive cells extending from the prefrontal to occipital cor-
tices and cerebellum, as well as the full extent of the spinal cord [73]. In
contrast, unilateral columnar intraparenchymal infusions of AAV9-GFP
resulted in amore localised GFP distribution, but with evidence of distal
transduction. A predominant neurotropism resulted from either route
of injection.
Subsequently therapeutic doses of both lentiviral and AAV9 derived
vectors, coding for untagged native proteins, were injected into both the
ventricles and brain parenchyma of pre-clinical CLN5 and CLN6 affected
lambs. All the CLN5 affected injected sheepwere indistinguishable from
normal age-matched control sheep at 18 months of age, clinically and
using the behavioural tests mentioned above, whilst the uninjected af-
fected sheep were at end-stage disease. Only one of the six injected
CLN6 affected sheep has had an outcome similar to the CLN5 injected
animals.Monitoring of the injected sheep continues. Because of their re-
markable health, previous plans to post-mortem these sheep 18months
after injection have been suspended, to allow us to gain an insight into
how long the treatment is effective for.Transparency Document
The Transparency document associated with this article can be
found, in the online version.
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